CFTR
51 programs · 49 companies
Programs
51
Companies
49
Active Trials
46
Targeting CFTR
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | Urothelial CaGBM | |
| Datoglumide | AbbVie | Approved | SLE | |
| SNY-7254 | Sanofi | Phase 2 | NASHFSGS | |
| SNY-5894 | Sanofi | Approved | FSGSRSV | |
| Sovarelsin | BioMarin | Phase 2 | PSP | |
| Fixatuximab | Legend Biotech | Preclinical | Parkinson'sFTD | |
| Doxasotorasib | Samsung Biologics | Phase 2/3 | AngelmanALL | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | MMWet AMD | |
| Cevicapivasertib | Corcept | Phase 2 | IPF | |
| BVN-7642 | Bavarian Nordic | Phase 2 | LGSParkinson's | |
| Fixaderotide | Ascletis | Phase 2 | Prostate CaWet AMD | |
| EOR-IIT-286 | EORTC | Preclinical | Dravet | |
| STA-IIT-542 | Stanford Medicine | Phase 2/3 | IgAN | |
| Tixatapinarof | Cargo Therapeutics | Approved | NMOSD | |
| VIG-1206 | Vigil Neuro | Phase 3 | ALSGIST | |
| Sovanesiran | Zentalis | Phase 1 | BCCIPF | |
| Taladerotide | Fractyl | Phase 2/3 | NASHNMOSD | |
| Pexatuximab | Soligenix | Phase 2 | MG | |
| EYE-3796 | Eyenovia | Phase 3 | NarcolepsyLGS | |
| ZYN-3484 | Zynerba Pharma | Phase 2/3 | Migraine | |
| GAL-3172 | Galena Biopharma | Preclinical | CKDCML | |
| Lisocagene | Caris Life Sciences | Phase 2/3 | PV | |
| Tirasotorasib | Galecto | Approved | MCL | |
| Zenomavacamten | Kumquat Bio | Phase 3 | MS | |
| MED-3086 | Medivation (Pfizer) | Preclinical | AMLALS | |
| SHI-2889 | Shire (Takeda) | Phase 2 | CKDFabry | |
| GLO-4270 | Gloria Biosciences | Phase 1 | DravetCTCL | |
| Ivozasiran | Alteogen | Phase 3 | ADPKD | |
| Rimanaritide | Kojin Ther | Phase 3 | MesoMDS | |
| TER-2947 | Terray Ther | Phase 3 | Urothelial Ca | |
| Nidazumab | Harmony Bio | Phase 2 | FabryIgAN | |
| Lisosotorasib | Ocuphire | Phase 3 | MCLPNH | |
| Zanutenlimab | CymaBay (Gilead) | Phase 2 | IgANMM | |
| Motainavolisib | Arbor Bio | Phase 1 | AsthmaMyelofibrosis | |
| Daramavacamten | Nichi-Iko | Preclinical | Wet AMDDravet | |
| Daratuximab | PeptiDream | Approved | DLBCLCML | |
| Riboderotide | PeptiDream | Phase 2 | ET | |
| 051-2746 | LG Chem Life | Phase 2/3 | MesoCervical Ca | |
| Polainavolisib | Oryzon Genomics | Preclinical | NMOSDCeliac | |
| Olpazumab | Bayer AG | Phase 1 | RB | |
| Tixarelsin | Summit Therapeutics | Phase 2/3 | EoEMCC | |
| Gelinaritide | Stallergenes Greer | Phase 2 | SMAMM | |
| Ivoinavolisib | Biogenesis Bago | Phase 2/3 | ADHDCeliac | |
| BIO-IIT-307 | Bio Farma | Phase 2/3 | Endometrial Ca | |
| RIK-IIT-829 | RIKEN | Phase 3 | MS | |
| FUD-IIT-666 | Fudan Cancer Hosp | Preclinical | Asthma | |
| SEV-IIT-582 | Severance Hospital | Preclinical | Crohn's | |
| HOS-IIT-667 | Hospital Israelita Einstein | Phase 3 | Wilms | |
| Adagraratamab | InnoCare | NDA/BLA | HSNB | |
| ZTS-9629 | Zoetis | Phase 3 | NMOSDAS | |
| Bemaratamab | Veeva Systems | Phase 2/3 | Urothelial CaEpilepsy |